Capricor Therapeutics Inc (NASDAQ:CAPR) saw an uptick in trading volume on Tuesday . 1,792,254 shares traded hands during mid-day trading, an increase of 464% from the previous session’s volume of 317,571 shares.The stock last traded at $3.10 and had previously closed at $2.72.
A number of brokerages recently commented on CAPR. HC Wainwright upped their price target on shares of Capricor Therapeutics from $3.50 to $12.40 and gave the company a “buy” rating in a research note on Monday, July 15th. Zacks Investment Research upgraded shares of Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research note on Tuesday, August 13th. ValuEngine upgraded shares of Capricor Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Maxim Group restated a “hold” rating on shares of Capricor Therapeutics in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $6.63.
The company has a market capitalization of $10.73 million, a PE ratio of -0.55 and a beta of 1.81. The stock’s 50 day moving average is $2.92 and its 200 day moving average is $2.06.
Capricor Therapeutics Company Profile (NASDAQ:CAPR)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Article: How to identify percentage decliners
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.